2026-05-22T04:07:45Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/186152024-09-21T18:35:44Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Martínez-Montoro, José Ignacio author Pinzón-Martín, José Luis author Damas-Fuentes, Miguel author Fernández-Valero, Andrea author Tinahones, Francisco J author 2022-04-14 Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome. 10.3389/fendo.2022.838887 1664-2392 Frontiers in endocrinology http://hdl.handle.net/10668/20559 35498407 http://hdl.handle.net/20.500.12105/18615 Type A insulin resistance syndrome diabetes glucagon-like peptide-1 receptor agonist insulin resistance sodium-glucose cotransporter 2 inhibitor Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.